



Session	Start-ups/SMEs looking for Finance: Pre-seed/Angel/Seed – Cosmetics & Personal Hygiene
Title	Mastitia – The World’s First Microbiome-Based Mastitis Prevention
Company	Mastitia Aps
Speaker	Emilie Glad Bak
TRL	TRL 4-7
Keywords feedstock (max 2)	Human microbiome
Keywords technology (max 2)	Postbiotic Strains
Keywords End-Product (max 2)	Prevention Cream
Abstract:	
Every year, 32 million breastfeeding mothers develop mastitis — a painful breast infection treated almost exclusively with antibiotics. Overuse of these antibiotics contributes to antimicrobial resistance (AMR), disrupts the infant microbiome, and causes 38% of mothers to stop breastfeeding prematurely. No preventive solution currently exists. Mastitia is the world's first microbiome-based mastitis prevention cream, developed from a 3,000-woman microbiome cohort. Our proprietary dual-strain postbiotic formula — derived directly from healthy women — is preclinically validated to suppress key mastitis pathogens, including antibiotic-resistant strains, significantly reducing the need for antibiotics without disrupting the natural microbiome. This is bioeconomy in action: replacing broad-spectrum antibiotics with precision, nature-derived biology that protects both mother and infant while actively combating AMR. With a US patent granted, FDA 510(k) pathway validated, and active commercial dialogues with leading maternal health and pharma partners, Mastitia is raising \$3M seed to scale commercial production, execute a pre-launch, and pursue medical device clearance in both the US (FDA 510(k)) and EU (CE/MDR) — unlocking prevention claims and the full global market opportunity. Mastitia is not just a product — it is a scalable biological platform with line extensions into nursing pads, oral capsules, therapeutics, and bovine mastitis, positioning us for a strategic acquisition.	